NDC 50242-007 – Enspryng
Satralizumab 120 mg/mL · Injection, Solution · Subcutaneous
Product NDC50242-007
Product details
- Brand name
- Enspryng
- Generic name
- Satralizumab
- Labeler
- Genentech, Inc.
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Marketing category
- BLA · BLA761149
- Marketed since
- August 14, 2020
- Listing expires
- December 31, 2027
Active ingredients
- Satralizumab 120 mg/mL
Package NDC codes (4)
| Package NDC | Description | Since |
|---|---|---|
| 50242-007-01 | 1 SYRINGE, PLASTIC in 1 CARTON (50242-007-01) / 1 mL in 1 SYRINGE, PLASTIC | Aug 14, 2020 |
| 50242-007-33 sample | 1 SYRINGE in 1 CARTON (50242-007-33) / 1 mL in 1 SYRINGE | Jun 10, 2026 |
| 50242-007-55 | 1 SYRINGE, PLASTIC in 1 CARTON (50242-007-55) / 1 mL in 1 SYRINGE, PLASTIC | Jun 10, 2026 |
| 50242-007-86 sample | 1 SYRINGE, PLASTIC in 1 CARTON (50242-007-86) / 1 mL in 1 SYRINGE, PLASTIC | Aug 13, 2021 |